# Metropolis Healthcare share price today (Metropolis Healthcare Ltd, NSE: METROPOLIS)

> Metropolis Healthcare share price today: ₹568.70 at the NSE close on 3 November 2026, up 15.4% in a year. Metropolis Healthcare (NSE: METROPOLIS) is worth ₹11,791 crore, trades at a P/E of 56.7 and has closed between ₹421.75 and ₹597.45 over the past 52 weeks. > Metropolis Healthcare Ltd's earnings have grown faster than its share price. Earnings per share grew +31.0% in a year while the price moved +15.4%. METROPOLIS · Diagnostics · data as of 3 November 2026. Page: https://www.sectoralpha.in/stocks/metropolis-healthcare-ltd

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Business trend: Mixed, from the last 12 quarters
- Price: ₹568.70 (+15.4% in a year)
- P/E: 56.7× (lower than 54% of the last 7.5 years)
- Revenue (Jun 2026): ₹450 Cr (+16.6% on a year ago)
- Profit (Jun 2026): ₹57.0 Cr (+26.7% on a year ago)
- Operating margin: 25.0% (+2.0 points on a year ago)
- ROCE: 18%, FY26
- ROIC: 14.9%, against a 12.0% cost of capital: +2.9 points

The main question: promoters moved −1.6 percentage points over 8 quarters while the business went the other way. ## What is the Metropolis Healthcare share price today? Metropolis Healthcare Ltd's share price was ₹568.70 at the close on 3 November 2026. It has been rising for 23 weeks. That is 6.8% above its average price over the last 200 trading days. In the last 52 weeks it traded between ₹422 and ₹597, and at that close it sat 84% of the way up from that low. Over the past 13 weeks it has done better than the NIFTY 500, and it has stayed ahead for 2 weeks in a row. Over the last 7.5 years the share price moved +134% while the NIFTY 500 moved +126%, so it is ahead of the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What changed at Metropolis Healthcare this quarter? Three changes stood out: revenue up on a year earlier for 11 quarters in a row (every quarter we can compare), highest quarterly profit in 15 quarters and promoters cut their stake by 1 points in one quarter. 1. Revenue up on a year earlier for 11 quarters in a row (every quarter we can compare) In the June 2026 quarter revenue was ₹450 crore, +16.6% on a year earlier. Why: Revenue rose because both new and older centers brought in more work. Next results: check whether adding centers without new labs keeps bringing in more work. From the earnings call on 5 Aug 2026. 2. Highest quarterly profit in 15 quarters Profit of ₹57 crore in the June 2026 quarter is the highest of the last 15 quarters. From the earnings call on 5 Aug 2026. 3. Promoters cut their stake by 1 points in one quarter From 48.9% to 47.8% in the September 2026 quarter. ## What are Metropolis Healthcare's latest quarterly results? For April to June 2026 (the quarter ended 30 June 2026), Metropolis Healthcare reported revenue of ₹450 crore, up 16.6% from ₹386 crore a year earlier, and a profit of ₹57.0 crore, up 26.7% from ₹45.0 crore. ### Metropolis Healthcare results: April to June 2026 against a year earlier

| Measure | April to June 2026 | April to June 2025 | Change |
| --- | --- | --- | --- |
| Revenue | ₹450 crore | ₹386 crore | +16.6% |
| Profit | ₹57.0 crore | ₹45.0 crore | +26.7% |
| Earnings per share | ₹2.73 | ₹2.17 | +25.8% |
| Operating margin | 25.0% | 23.0% | +2.0 points |

The next results, for July to September 2026, are due by 14 November 2026: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter). Metropolis Healthcare's management discussed these results on a call held on 5 August 2026; what it said is further down this page. (From the company's reported quarterly results (quarter ended 30 June 2026). Revenue and profit in ₹ crore.)

## What is the Metropolis Healthcare share price history? Metropolis Healthcare closed at ₹568.70 on 3 November 2026, up 15.4% from ₹492.60 a year earlier (31 October 2025) and down 25.3% over five years. Its highest weekly close since April 2019 was ₹860.23 on 31 December 2021. ### Metropolis Healthcare share price: then and now

| When | Close | Change to 3 Nov 2026 |
| --- | --- | --- |
| 1 week ago · 23 Oct 2026 | ₹522.95 | +8.7% |
| 1 month ago · 1 Oct 2026 | ₹537.90 | +5.7% |
| 6 months ago · 30 Apr 2026 | ₹476.50 | +19.3% |
| 1 year ago · 31 Oct 2025 | ₹492.60 | +15.4% |
| 3 years ago · 3 Nov 2023 | ₹368.11 | +54.5% |
| 5 years ago · 4 Nov 2021 | ₹761.63 | −25.3% |
| Earliest weekly close in our records · 18 Apr 2019 | ₹242.61 | +134.4% |
| Highest weekly close since April 2019 · 31 Dec 2021 | ₹860.23 | −33.9% |
| Lowest weekly close since April 2019 · 17 May 2019 | ₹229.99 | +147.3% |
| 52-week high (weekly close) · 18 Sep 2026 | ₹597.45 | −4.8% |
| 52-week low (weekly close) · 2 Apr 2026 | ₹421.75 | +34.8% |

Weekly closing prices, adjusted for splits and bonuses so every price is on today’s share count. Each change is the move from that price to the 3 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes. (402 weekly closes from 18 April 2019 to 3 November 2026.)

## What is the latest news on Metropolis Healthcare? 9 Nov 2026: Coming up: ex-date for an interim dividend of ₹1 a share. 3 Nov 2026: Metropolis Healthcare closed at ₹568.70, up 8.7% on the week and up 5.7% on the month. ### Earlier

- 5 Aug 2026: Metropolis Healthcare held its results call for April to June 2026. Management guided: FY27 revenue growth 14-16% in prepared remarks. - Results for April to June 2026: Revenue up 16.6% and profit up 26.7% on a year earlier. - Our read, 31 May 2026: FY26 organic revenue +13.7% (beat guidance of 12-13%), organic operating margin 25.9% (+140 basis points), profit ₹191 crore (+31% on a year earlier), Q4 profit ₹51 crore (+75% on a year earlier) , .,Core Diagnostics turned operating profit-positive (high single-digit in Q4 from -2% at acquisition), eliminating the margin drag; group operating margin goal 27-28% set for FY27-29 , .,Management credibility undermined by three documented goal changes on Core Diagnostics margin, center-to-lab ratio, and M&A moratorium in the past four concalls , . - 19 May 2026: ex-date for an interim dividend of ₹1 a share. - 20 Mar 2026: Bonus issue: 3 new shares for every 1 held (ex-date). - 11 Nov 2025: ex-date for an interim dividend of ₹4 a share. ### Our read of the business

FY26 organic revenue +13.7% (beat guidance of 12-13%), organic operating margin 25.9% (+140 basis points), profit ₹191 crore (+31% on a year earlier), Q4 profit ₹51 crore (+75% on a year earlier) , .,Core Diagnostics turned operating profit-positive (high single-digit in Q4 from -2% at acquisition), eliminating the margin drag; group operating margin goal 27-28% set for FY27-29 , .,Management credibility undermined by three documented goal changes on Core Diagnostics margin, center-to-lab ratio, and M&A moratorium in the past four concalls , . January to March 2026: FY26 execution confirmed; 3-year roadmap published with quantified goals. (Our read after the January to March 2026 results, written 31 May 2026. The April to June 2026 results are out since, so this part may be out of date until we update it.)

## What dividend does Metropolis Healthcare pay? Metropolis Healthcare paid ₹2 a share in regular dividends in the 12 months to 4 November 2026 (2 payments), a yield of 0.35% at the ₹568.70 close on 3 November 2026. The last was an interim dividend of ₹1 a share, ex-date 19 May 2026. Next: ₹1 a share, ex-date 9 November 2026. ### Metropolis Healthcare dividends since 1 April 2021

| Ex-date | Dividend per share | Type | Record date |
| --- | --- | --- | --- |
| 9 Nov 2026 (upcoming) | ₹1 | Interim | same day |
| 19 May 2026 | ₹1 | Interim | same day |
| 11 Nov 2025 | ₹4 | Interim | same day |
| 17 Nov 2023 | ₹4 | Interim | same day |
| 23 Feb 2023 | ₹8 | Interim | same day |
| 21 Feb 2022 | ₹8 | Interim | 22 Feb 2022 |

Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date. 1 of the last 12 months' payments came before a split or bonus; the 12-month total above is on today’s share count. 4 of 5 Of the last 5 financial years, years with an NSE dividend record

Yes. Metropolis Healthcare Ltd paid out 55% of its profit as dividends in FY26, and it paid a dividend in 10 of its last 13 reported years. (From the NSE corporate-actions record, read 4 November 2026.)

## What did Metropolis Healthcare management say on the latest results call? On the call for April to June 2026, held on 5 August 2026, Metropolis Healthcare's management guided: FY27 revenue growth 14-16% in prepared remarks. > “We believe this is a good start to our year and that we can sustain a revenue growth outlook of 14-16% for the year, which we expect to be primarily driven by volume growth.”
> Ameera Shah, on the call for April to June 2026

### What management guided

- FY27 operating margin expansion 100-150 basis points in prepared remarks. - Consolidated operating margin planned at 27-28% over this and next year; Core margin around 25% within 3-4 years of acquisition. - FY27 network: approximately 400-500 Tier 2 and Tier 3 openings in prepared remarks. - Specialty portfolio contribution planned at 45% from 40% currently. Management’s own plans and goals, from our notes of the call. A plan is not a result. Source: [the call transcript](https://files.tijorifinance.com/insight/india/7780/Conference Call/CC-Aug26.pdf). (From the call for April to June 2026, 5 August 2026.)

## What is the future of Metropolis Healthcare? What is changing in the business? What is changing at Metropolis Healthcare, from the latest results and calls: operating leverage on fixed lab base, specialty and true health mix shift and core diagnostics integration, margin drag to contributor. - Operating Leverage on Fixed Lab Base. 212 labs absorbing 14-15% volume growth without proportional cost additions; lab productivity +14% FY26; FY27 no new labs guided. ⚠ estimate
- Specialty and True Health Mix Shift. Specialty at 37% organic FY26 (+16% on a year earlier), aiming for 40% FY27; True Health 19% organic (+21% on a year earlier), aiming for 25%+ in 2-3 years, both improve RPP and gross margins. ⚠ estimate
- Core Diagnostics Integration, Margin Drag to Contributor. Core Diagnostics operating profit moved from -2% at acquisition to high single-digit January to March 2026; 20%+ goal by FY28-end removes acquired revenue from margin drag. ⚠ estimate

We check 16 kinds of change in every company, such as costs spread over more sales, higher-value products, new orders, new regions or falling debt, against its reported numbers and what management said on its calls. Only changes the numbers back are shown. (Our read after the January to March 2026 results, written 31 May 2026. The April to June 2026 results are out since, so this part may be out of date until we update it.)

## What could change the Metropolis Healthcare story? What are the risks? GST and labor code represent two policy levers that affect margins; labor code recurring impact ₹5-6 Cr annually already absorbed. ### The main risks

- : GST and labor code represent two policy levers that affect margins; labor code recurring impact ₹5-6 Cr annually already absorbed. ✓ fact

(Our read after the January to March 2026 results, written 31 May 2026. The April to June 2026 results are out since, so this part may be out of date until we update it.)

## What to watch in Metropolis Healthcare's next results? When Metropolis Healthcare reports July to September 2026, these are the 4 checks that show whether the story is still on course. First: Q2 volume growth to remain broad-based beyond seasonal strength; check mature-center productivity against new-center ramp. - What to check (from the call)
- Q2 volume growth to remain broad-based beyond seasonal strength; check mature-center productivity against new-center ramp. - Core integration to translate into nationwide specialty cross-sales and margin progression; check network utilization gains. - Center additions and rationalization to improve utilization without new lab expansion; check center-to-lab productivity. - True Health traction in Tier 2 and Tier 3 towns to widen beyond major cities; check wellness package adoption. ## Which stock lists is Metropolis Healthcare on? Metropolis Healthcare is not on any of our India lists this week. ## Is Metropolis Healthcare profitable? Metropolis Healthcare Ltd earned ₹57.0 Cr of net profit in the Jun 2026 quarter, +26.7% on the same quarter a year earlier. That is the 5th quarter in a row of profit growth. Full-year FY26 profit was ₹191 Cr. Over 10 years profit has grown 8.8% a year on average. That is 12.7% of the quarter's revenue. The same quarter a year earlier earned ₹45.0 Cr. For the full year, FY26 profit was ₹191 Cr (+30.8% on the year before). Why profit moved: revenue changed +16.6% on a year earlier and the margin moved +2.0 percentage points. Most of the change came from keeping more of each sale. On average over the last four quarters, profit changed +37.7% and revenue +22.0%. Profit is growing faster than sales: fixed costs are spread over more sales, so each extra rupee of revenue adds more to profit. ## How much revenue does Metropolis Healthcare make, and is it growing? Metropolis Healthcare Ltd reported ₹450 Cr of revenue in the Jun 2026 quarter, +16.6% on the same quarter a year earlier. That is the 12th quarter in a row with growth on the year before. Over 10 years it has grown 13.2% a year on average. The last full year, FY26, came in at ₹1,646 Cr. The last four reported quarters add to ₹1,710 Cr. FY26 revenue was ₹1,646 Cr, +23.7% on the year before. Recent pace: the last four quarters grew +22.0% on average, against 13.2% a year over the longer run, so this year is growing faster than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +21.8%, against +17.3% a year over the last 8 quarters (accelerating); profit over the last 12 months grew +33.6%, against +21.3% a year (accelerating). ## How much of every ₹100 of sales does Metropolis Healthcare keep? Metropolis Healthcare Ltd's operating margin was 25.0% in the Jun 2026 quarter, 2.0 percentage points higher than the same quarter a year ago. Across 13 years it has been between 23.0% and 29.0%. The latest quarter is within that range. Why this happened. Metropolis shifted from expansion-led capex to utilization-led productivity. FY26 saw 14-15% volume growth absorbed by the existing 212-lab network with capex of Rs 65 Cr. Lab productivity improved 14% on the same fixed base. Q4 organic margin 27.2% was driven by this operating leverage. FY27 guidance of 125-150 bps margin improvement assumes continued fixed-cost leverage as volumes grow 8-9% on top of the FY26 base. Why the margin moved: operating margin changed +1.4 percentage points on the year while gross margin changed +1.1 points. So the gain came mostly from the gross margin, which means input costs and prices charged. ## Is Metropolis Healthcare's profit turning into cash? Over the last 3 years, 189% of Metropolis Healthcare Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹351 Cr of operating cash against ₹191 Cr of profit. After ₹288 Cr of spending on assets, ₹63.0 Cr was left over as free cash. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why 189% of profit came in as cash: the cash cycle stayed about the same between FY21 and FY26, so the cash follows profit, not the cycle. What to look at next: the bigger use of cash is spending on new assets, at 2.4× depreciation over three years. The next section checks what that spending is building. ## Where does Metropolis Healthcare's cash go? Metropolis Healthcare Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was −57 days in FY26, down from −56 days in FY21. It spent ₹797 Cr on assets over the last 3 years. Customers take 38 days to pay, and stock sits for 51 days on average. At FY26 sales of ₹1,646 Cr, each day of that cycle ties up about ₹4.5 Cr, so roughly −₹257 Cr is tied up in the business at any time. FY26: customers took 38 days to pay and stock sat for 51 days, about 1.7 months of sales sitting as stock, for a full cycle of −57 days, shorter than FY21's −56. The full loop: cash goes out to suppliers and production on day 0. Stock sits for 51 days. Customers pay about 38 days after that. Suppliers are paid at 146 days. Together that makes the −57-day cycle. Spending on assets: ₹797 Cr over the last 3 years, against ₹337 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹0.0 Cr (FY26): assets paid for that are not earning yet. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is Metropolis Healthcare's P/E ratio, and how does it compare with its own history? Metropolis Healthcare Ltd's P/E is 56.7×, in the middle of its own history: higher than 46% of past readings. Its usual P/E (the middle reading) is 58.2×, over 7.5 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. Why this happened. Digital revenue reached 25% of total FY26 revenue via three channels: Metropolis app, website, and a CLM engine for retention. Management differentiates Metropolis digital from pure-play health-tech competitors via the physical brand's lower customer acquisition cost and higher customer lifetime value. The unit economics argument is plausible given the 50+ year brand and 750-town presence, though management has not quantified the CAC differential in any concall. The P/E here, and its history, use a profit figure that can leave out one-off items, so it can differ from a P/E worked out on the quarterly results. Those results' earnings per share for the four quarters to Jun 2026 add up to ₹9.73. Why the multiple is where it is: over the past year earnings per share moved +31.0% while the price moved +15.4%. Earnings did better than the price, which pulled the multiple down within its own range. Where the price move came from: over 5 years the price moved −5.7% a year; about −3.4% a year came from earnings growth and about −2.3 percentage points from the multiple (the market paying less). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple. In short: the multiple is about average against its own past, so the earnings trend underneath matters more than the multiple. ## Is the Metropolis Healthcare business getting better or worse? Metropolis Healthcare Ltd's business is giving mixed signals. There is no clear direction across the growth lines, with ROCE rising at 17.9%; each line tells part of the story. This is based on 12 quarters of 4 measures. Why it matters: when the lines disagree, each line above matters more than any single label. ## What is the Metropolis Healthcare story, and has it been checked? Metropolis Healthcare Ltd's story is not scored yet against the checks our research set on 31 May 2026. Where it sits in its own cycle: Not stated in the research file. Still open: Three documented management consistency failures in four concalls, Core Diagnostics margin goal, center-to-lab ratio timeline, and M&A moratorium, all on core thesis pillars. Our read, 31 May 2026. What is proven. What is not proven yet. Three documented management consistency failures in four concalls, Core Diagnostics margin goal, center-to-lab ratio timeline, and M&A moratorium, all on core thesis pillars. What the company does. FY26 organic revenue +13.7% (beat guidance of 12-13%), organic EBITDA margin 25.9% (+140bps), PAT Rs 191 Cr (+31% YoY), Q4 PAT Rs 51 Cr (+75% YoY) , . Core Diagnostics turned EBITDA-positive (high single-digit in Q4 from -2% at acquisition), eliminating the margin drag; group EBITDA margin goal 27-28% set for FY27-29 , . Management credibility undermined by three documented goal changes on Core Diagnostics margin, center-to-lab ratio, and M&A moratorium in the past four concalls , . Lever 1 · Operating leverage: building. 212 labs absorbing 14-15% volume growth without proportional cost additions; lab productivity +14% FY26; FY27 no new labs guided. What proves it keeps working: Operating Leverage on Fixed Lab Base. It stops working if Two consecutive quarters of Core Diagnostics missing its stated improvement path, OR organic EBITDA margin declining versus FY26 exit rate. Lever 2 · Value-added mix: building. Specialty at 37% organic FY26 (+16% YoY), aiming for 40% FY27; True Health 19% organic (+21% YoY), aiming for 25%+ in 2-3 years, both improve RPP and gross margins. What proves it keeps working: Specialty and True Health Mix Shift. It stops working if Two consecutive quarters of Core Diagnostics missing its stated improvement path, OR organic EBITDA margin declining versus FY26 exit rate. Lever 3 · Management change: building. Core Diagnostics EBITDA moved from -2% at acquisition to high single-digit Q4 FY26; 20%+ goal by FY28-end removes acquired revenue from margin drag. What proves it keeps working: Core Diagnostics Integration, Margin Drag to Contributor. It stops working if Two consecutive quarters of Core Diagnostics missing its stated improvement path, OR organic EBITDA margin declining versus FY26 exit rate. Lever 8 · Demerger or value unlock: building. Digital at 25% of FY26 revenue; physical brand reduces customer acquisition cost versus health-tech competitors; CLM engine improving retention. What proves it keeps working: Digital Channel Scale, Lower CAC, Higher LTV. It stops working if Two consecutive quarters of Core Diagnostics missing its stated improvement path, OR organic EBITDA margin declining versus FY26 exit rate. Sources: our stock research file (31 May 2026) · quarterly results through Jun 2026 · the company’s own earnings calls. The story check is re-scored every results season; the record below never changes. ## Did Metropolis Healthcare management deliver what it promised? What Metropolis Healthcare Ltd's management promised, against what actually happened: 4 promises on the record. Read straight from the company’s own earnings calls. A promise that slipped stays on this page after it is met. Pricing History Rewritten · 5 August 2026. In May 2026, management said Metropolis had taken a price increase every year over the prior 2-3 years and that only the current year had been deferred. The August 2026 call instead said the last increase occurred in January 2023, which implies no increases during the intervening period and materially changes the basis for analyzing realization growth. Center-to-Lab Ratio Reporting Reversed · 5 August 2026. May 2026 reported that the center-to-lab ratio had improved to 24:1, whereas the August 2026 call reported a current ratio of 1:21 while also claiming it had improved from 1:21 a year earlier. Even allowing for notation differences, the reported current figure has moved from 24 centers per lab to 21 centers per lab without an explanation of a changed definition, acquisition impact, or lab consolidation methodology. Specialty Mix Goal Raised Without Reconciliation · 5 August 2026. In May 2026, management expected specialty to reach approximately 40% of revenue for the year. By August 2026, management was already reporting a 40% contribution and had raised the stated goal to 45%, a material five-point increase with no explanation of what changed or how the higher goal affects the growth and realization outlook. Core Diagnostics Long-Term Margin Goal Downgraded · 14 May 2026. In the Nov 2025 call, management explicitly stated that Core Diagnostics would be brought to Metropolis levels of margin within 3 years of the acquisition, and directly confirmed the specific ~23-24% figure when asked by an analyst. In the May 2026 call, this same 3-year commitment is repositioned as 20% plus EBITDA for Core - a materially lower threshold that now sits well below Metropolis's own FY26 organic margin of 25.9%, with no explanation offered for the reduced ambition. Every quote above is taken word for word from the company’s own earnings calls. ## How much does Metropolis Healthcare earn on its capital? Metropolis Healthcare Ltd earned a ROCE of 18% in FY26. That is up from a low of 15% in FY25. Its return on capital used (ROIC) is 2.9 percentage points above its cost of capital, so growth here adds value, not just size. It comes from a 11.6% net margin and 0.77× asset turnover (sales divided by assets). Why the return is what it is (FY26): a 11.6% net margin × 0.77× asset turnover × 1.41× leverage (assets divided by equity) ≈ 12.6% on equity. The margin does its share; borrowing plays a small part, so this return is earned, not borrowed. The key test, return on capital used minus the cost of capital: 14.9% − 12.0% = +2.9 percentage points. The 12.0% is a standard assumption for the cost of capital in India, not an estimate for this company. Read the sign and size of the gap, not the decimals. Positive but thin: it creates value with little room for error. The 14.9% ROIC above is the latest reading, as reported. The yearly chart below shows FY26 at 13.3%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method. ## Does Metropolis Healthcare have too much debt? Metropolis Healthcare Ltd has total debt of ₹232 Cr against shareholder equity of ₹1,525 Cr as of Jun 2026, so its debt is 0.15× its equity, which is very little. Year by year, that ratio went from 0.43 in FY22 to 0.15 in FY26. So the returns on this page come from the business, not from borrowed money. ## What is the Metropolis Healthcare shareholding pattern? Domestic institutions raised their stake in Metropolis Healthcare Ltd by 7.5 percentage points over 8 quarters, the biggest change among its owners. Domestic institutions now own 35.5% of the company. Foreign institutions moved −6.9 points over the same period, to 11.7%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings. Why this happened. Core Diagnostics was acquired at -2% EBITDA margins and has completed its 4-quarter turnaround commitment, exiting Q4 FY26 at high single-digit margins. The path to 20%+ by end of FY28 via platform integration and procurement synergies is articulated. However, the original guidance was for Core Diagnostics to achieve Metropolis-level margins (~23-24%) within 3 years; this was downgraded to 20%+ in May 2026 without explanation, reducing the magnitude of this driver. Regional acquisitions are performing above group average margins. Over the last two years: Domestic institutions: +7.5 points over 8 quarters, to 35.5%; Foreign institutions: −6.9 points over 8 quarters, to 11.7%; Promoters: −1.6 points over 8 quarters, to 47.8%. Why the owners changed: foreign institutions moved −6.9 points and domestic institutions +7.5 points over 8 quarters, while promoters moved −1.6 points. One group of institutions took over shares from the other; it is not a change of mind by the people running the company. ## How far is Metropolis Healthcare from balance-sheet trouble? For Metropolis Healthcare Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date. ## How does Metropolis Healthcare rank in its industry? 64.6 out of 100, rank 2 of 9 in Diagnostics, with 96% of the evidence available. Metropolis Healthcare Ltd scores 64.6 out of 100 against the 9 companies it is compared with in Diagnostics, ranking 2. The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. The four parts add up to the total exactly: 25.7 + 14.1 + 13.3 + 11.5 = 64.6. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Metropolis Healthcare compared with? Metropolis Healthcare ranks 2 of 9 Diagnostics companies on the 4-Factor Sector Score, with 64.6 out of 100. 1. [One Global Service Provider Ltd](https://www.sectoralpha.in/stocks/one-global-service-provider-ltd) ONEGLOBAL · quiet · Most evidence points up · 81% evidence 70.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 30.1/35 · Revenue 100% · Profit 100% · Operating margin change 4 points · 88% evidence Capital efficiency 14.1/25 · ROCE 87% · Operating margin 19% · 100% evidence Valuation 18.5/20 · P/E 11.6× · PEG 0.45 · 100% evidence Relative strength 7.5/20 · Lead over its industry n/a · Lead over NIFTY 500 -18.5% · 1 year 24.8% · 25% evidence · 0 of 5 weeks ahead Exact sum: 30.1 + 14.1 + 18.5 + 7.5 = 70.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 2. Metropolis Healthcare Ltd this page METROPOLIS · turning · Evidence leans up · 96% evidence 64.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 25.7/35 · Revenue 21.8% · Profit 33.5% · Operating margin change 2 points · 88% evidence Capital efficiency 14.1/25 · ROCE 17.8% · Operating margin 25% · 100% evidence Valuation 13.3/20 · P/E 54.4× · PEG 1.08 · 100% evidence Relative strength 11.5/20 · Lead over its industry 3.2% · Lead over NIFTY 500 11.6% · 1 year 10.8% · 100% evidence · 4 of 12 weeks ahead Exact sum: 25.7 + 14.1 + 13.3 + 11.5 = 64.6 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 3. [Thyrocare Technologies Ltd](https://www.sectoralpha.in/stocks/thyrocare-technologies-ltd) THYROCARE · quiet · Evidence leans up · 100% evidence 60.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 22.0/35 · Revenue 22% · Profit 12.6% · Operating margin change 0 points · 100% evidence Capital efficiency 21.3/25 · ROCE 35.4% · Operating margin 33% · 100% evidence Valuation 12.6/20 · P/E 41.5× · PEG 1.1 · 100% evidence Relative strength 4.1/20 · Lead over its industry -6.7% · Lead over NIFTY 500 0.5% · 1 year -2% · 100% evidence · 7 of 12 weeks ahead Exact sum: 22 + 21.3 + 12.6 + 4.1 = 60 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 4. [Vijaya Diagnostic Centre Ltd](https://www.sectoralpha.in/stocks/vijaya-diagnostic-centre-ltd) VIJAYA · leader · Evidence leans up · 96% evidence 59.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.1/35 · Revenue 20.2% · Profit 23.8% · Operating margin change 4 points · 88% evidence Capital efficiency 16.4/25 · ROCE 20.5% · Operating margin 43% · 100% evidence Valuation 0.3/20 · P/E 79.4× · PEG 4.13 · 100% evidence Relative strength 18.7/20 · Lead over its industry 18.1% · Lead over NIFTY 500 26.8% · 1 year 46.2% · 100% evidence · 12 of 12 weeks ahead Exact sum: 24.1 + 16.4 + 0.3 + 18.7 = 59.5 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 5. [Suraksha Diagnostic Ltd](https://www.sectoralpha.in/stocks/suraksha-diagnostic-ltd) SURAKSHA · breaking out · Evidence leans up · 89% evidence 57.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 19.3/35 · Revenue 23% · Profit 9.4% · Operating margin change 2 points · 88% evidence Capital efficiency 11.7/25 · ROCE 17.3% · Operating margin 35% · 100% evidence Valuation 8.9/20 · P/E 46× · PEG 1.66 · 65% evidence Relative strength 17.2/20 · Lead over its industry 6.7% · Lead over NIFTY 500 15.6% · 1 year -0.5% · 100% evidence · 10 of 12 weeks ahead Exact sum: 19.3 + 11.7 + 8.9 + 17.2 = 57.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 6. [Dr Lal Pathlabs Ltd](https://www.sectoralpha.in/stocks/dr-lal-pathlabs-ltd) LALPATHLAB · leader · Evidence leans up · 96% evidence 56.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 12.4/35 · Revenue 14.3% · Profit 5% · Operating margin change 2 points · 88% evidence Capital efficiency 18.5/25 · ROCE 28% · Operating margin 31% · 100% evidence Valuation 9.3/20 · P/E 56.9× · PEG 1.29 · 100% evidence Relative strength 16.5/20 · Lead over its industry 15.5% · Lead over NIFTY 500 24.4% · 1 year 21.6% · 100% evidence · 12 of 12 weeks ahead Exact sum: 12.4 + 18.5 + 9.3 + 16.5 = 56.7 · What this means: Relative strength against the index is 24.4%, and revenue and profit growth are weak. 7. [3B Blackbio DX Ltd](https://www.sectoralpha.in/stocks/3b-blackbio-dx-ltd) 3BBLACKBIO · breaking out · Evidence leans up · 78% evidence 50.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 15.8/35 · Revenue 54.3% · Profit 14.7% · Operating margin change -27.8 points · 83% evidence Capital efficiency 16.6/25 · ROCE 25.5% · Operating margin 25.4% · 76% evidence Valuation 9.5/20 · P/E 20× · PEG n/a · 50% evidence Relative strength 9.0/20 · Lead over its industry -7% · Lead over NIFTY 500 1.2% · 1 year -5.9% · 100% evidence · 10 of 12 weeks ahead Exact sum: 15.8 + 16.6 + 9.5 + 9 = 50.9 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 8. [Krsnaa Diagnostics Ltd](https://www.sectoralpha.in/stocks/krsnaa-diagnostics-ltd) KRSNAA · breaking out · Evidence leans down · 81% evidence 49.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 13.7/35 · Revenue 10.3% · Profit 21% · Operating margin change -2 points · 88% evidence Capital efficiency 9.1/25 · ROCE 12.7% · Operating margin 25% · 100% evidence Valuation 18.9/20 · P/E 16.8× · PEG 0.57 · 100% evidence Relative strength 7.9/20 · Lead over its industry n/a · Lead over NIFTY 500 -13.7% · 1 year -35.1% · 25% evidence · 1 of 12 weeks ahead Exact sum: 13.7 + 9.1 + 18.9 + 7.9 = 49.6 · What this means: The valuation scores well, but earnings are not improving yet, so the business does not back up the low multiple so far. 9. [Vimta Labs Ltd](https://www.sectoralpha.in/stocks/vimta-labs-ltd) VIMTALABS · quiet · Most evidence points down · 100% evidence 30.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 8.3/35 · Revenue 11.7% · Profit 2.5% · Operating margin change 0 points · 100% evidence Capital efficiency 15.7/25 · ROCE 25.2% · Operating margin 34% · 100% evidence Valuation 4.6/20 · P/E 26.6× · PEG 2.75 · 100% evidence Relative strength 1.5/20 · Lead over its industry -12.6% · Lead over NIFTY 500 -5.4% · 1 year -33.2% · 100% evidence · 8 of 12 weeks ahead Exact sum: 8.3 + 15.7 + 4.6 + 1.5 = 30.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Diagnostics](https://www.sectoralpha.in/sectors/diagnostics), all 9 compared on one page. ## Which companies are close to Metropolis Healthcare in size? Metropolis Healthcare is the 3rd largest of 9 Diagnostics companies on Sector Alpha by market value (scores of 30 October 2026). Just above it: Dr Lal Pathlabs and Vijaya Diagnostic Centre. Just below it: Thyrocare Technologies, Vimta Labs, Suraksha Diagnostic and Krsnaa Diagnostics. ### Diagnostics companies close in size

1. [Dr Lal Pathlabs Ltd](https://www.sectoralpha.in/stocks/dr-lal-pathlabs-ltd) ₹31,999 crore
2. [Vijaya Diagnostic Centre Ltd](https://www.sectoralpha.in/stocks/vijaya-diagnostic-centre-ltd) ₹14,890 crore
3. Metropolis Healthcare Ltd ₹11,320 crore
4. [Thyrocare Technologies Ltd](https://www.sectoralpha.in/stocks/thyrocare-technologies-ltd) ₹7,263 crore
5. [Vimta Labs Ltd](https://www.sectoralpha.in/stocks/vimta-labs-ltd) ₹2,168 crore
6. [Suraksha Diagnostic Ltd](https://www.sectoralpha.in/stocks/suraksha-diagnostic-ltd) ₹1,648 crore
7. [Krsnaa Diagnostics Ltd](https://www.sectoralpha.in/stocks/krsnaa-diagnostics-ltd) ₹1,634 crore

[All 9 Diagnostics companies, largest first](https://www.sectoralpha.in/sectors/diagnostics#all-companies)

### Companies close in size in other industries

1. [KSB Ltd](https://www.sectoralpha.in/stocks/ksb-ltd) ₹11,332 crore · Pumps
2. [Va Tech Wabag Ltd](https://www.sectoralpha.in/stocks/va-tech-wabag-ltd) ₹11,330 crore · Water Treatment
3. Metropolis Healthcare Ltd ₹11,320 crore
4. [Bikaji Foods International Ltd](https://www.sectoralpha.in/stocks/bikaji-foods-international-ltd) ₹11,317 crore · FMCG - Snacks
5. [Karnataka Bank Ltd](https://www.sectoralpha.in/stocks/karnataka-bank-ltd) ₹11,284 crore · Banks - Private

## What else do people ask about Metropolis Healthcare? ### What is Metropolis Healthcare's share price today? Metropolis Healthcare Ltd's share price is ₹568.70, +15.4% over the past year. The whole company is worth ₹11,791 Cr on the market. In the last 52 weeks it traded between ₹422 to ₹597; today it is 84% of the way up from the low, 6.8% above its 200-day average (as of 3 November 2026). ### What were Metropolis Healthcare's latest quarterly results? Metropolis Healthcare Ltd reported revenue of ₹450 Cr and net profit of ₹57.0 Cr for the Jun 2026 quarter. Revenue rose 16.6% and profit rose 26.7% compared with a year earlier. Earnings per share were ₹2.73. The operating margin was 25.0%, 2.0 percentage points higher than a year earlier (as of 3 November 2026). ### What is Metropolis Healthcare's market cap? Metropolis Healthcare Ltd's market capitalisation is ₹11,791 Cr at a share price of ₹568.70. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### How is Metropolis Healthcare performing? Metropolis Healthcare Ltd's share price has been rising for 23 weeks. In its latest quarter, revenue rose 16.6% and profit rose 26.7% compared with a year earlier. Over the past 13 weeks it has done better than the NIFTY 500, for 2 weeks running (as of 3 November 2026). ### Will Metropolis Healthcare's share price go up? This page does not forecast Metropolis Healthcare Ltd's share price. What it shows instead: the share price is ₹568.70, and it has been rising for 23 weeks. Its P/E of 56.7× is higher than 46% of its own last 8 years (as of 3 November 2026). ### Who owns Metropolis Healthcare? Promoters own 47.8% of Metropolis Healthcare Ltd, foreign institutions 11.7%, domestic institutions 35.5% and the public 5.0% (latest quarter). The biggest change over the last two years: Domestic institutions raised their stake by 7.5 percentage points over 8 quarters (as of 3 November 2026). ### Does Metropolis Healthcare have too much debt? No, Metropolis Healthcare Ltd has little debt: its debt is 0.15× its equity, and its operating profit is 14 times its interest bill. FY26 borrowings were ₹232 Cr against equity of ₹1,513 Cr. So the returns on this page come from the business, not borrowed money (as of 3 November 2026). ### Where is Metropolis Healthcare in its business cycle? Metropolis Healthcare Ltd's FY26 operating margin was 25.0%, against a 13-year range of 23.0% to 29.0%: the middle of its own range, neither a peak nor a low. The latest quarter was 25.0%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 3 November 2026). ### What could break the Metropolis Healthcare story? The main question: promoters moved −1.6 percentage points over 8 quarters while the business went the other way. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is Metropolis Healthcare a stock worth studying right now? What the numbers show: Metropolis Healthcare Ltd's earnings have grown faster than its share price. Earnings per share grew +31.0% in a year while the price moved +15.4%. The main open question: whether the owners’ moves turn back in line with the business. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). ### Is there a Metropolis Healthcare share price forecast for 2026? What management itself guided: FY27 revenue growth 14-16% in prepared remarks. What is changing at Metropolis Healthcare, from the latest results and calls: operating leverage on fixed lab base, specialty and true health mix shift and core diagnostics integration, margin drag to contributor. What would change the story: GST and labor code represent two policy levers that affect margins; labor code recurring impact ₹5-6 Cr annually already absorbed. This is research, not advice. We’re not SEBI-registered.